A&M's Research Integration Center, which will house data and act as an innovation hub for innovators and military specialists, is expected to be completed next fall. Photo via tamu.edu

Texas A&M University is in the process of building a $200 million, multi-building facility just off its main campus in College Station and Bryan, Texas. As of this week, the project has fresh funds from the A&M Board of Regents to continue on with construction.

The board approved a $60.3 million projects at the George H.W. Bush Combat Development Complex, or BCDC, on the RELLIS Campus in Bryan, according to a press release from the university. According to a news release from the university, $22.5 million approved will go toward hypersonic and directed energy testing range called BAM — which stands for Ballistic, Aero-Optics, and Materials. At one kilometer long and two meters in diameter, BAM is expected to the largest enclosed hypersonic testing facility in the nation.

"There will be no other place like it in the world," says John Sharp, chancellor of the Texas A&M System, in the release.

BAM's construction is scheduled to begin in February — with completion by October 2022.

The other $37.8 million of the recent funds approved will go toward for a vehicle test track called the Innovation Proving Ground, or IPG. That's set to break ground in May 2021, and completion is expected a year later.

In addition to the construction at the BCDC, A&M's RELLIS Campus is also working on a few military innovation projects. Construction is currently underway on the Research Integration Center, or RIC, that will house all the data for the BCDC and act as a place to meet and collaborate for innovators and government personnel. The three-story innovation hub broke ground in October 2019 and is expected to be completed in the fall of 2021.

The complex is being supported by an initial $135 million investment from the state of Texas, the Texas A&M Engineering Experiment Station, and the Texas A&M University System. The U.S. Army Futures Command, or AFC) will invest up to $65 million over five years.

The plans come from a collaboration between the AFC, the U.S. Army Combat Capabilities Development Command Army Research Laboratory, other military branches, NASA, and other federal agencies, according to a release.

"Some universities talk about, 'Here's what we are going to do for you,'" says Sharp, in a release. "At Texas A&M, we ask, 'What do you want us to do for you?'"

Texas A&M's RELLIS campus sits about 10 miles down the road from the main campus. Photo via tamu.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.